CVRx receives Category I code for Barostim, says Cantor Fitzgerald

Cantor Fitzgerald reiterated an Overweight rating and $14 price target on CVRx (CVRX) shares following the announcement that the American Medical Association CPT Editorial Panel has approved new Category I CPT codes for Barostim, which are expected to be implemented on January 1, 2026. The transition of Barostim to Category I codes from Category III reflects the increased adoption and validation of Barostim in treating symptoms of heart failure, as Category III aren’t as easily reimbursable as Category I codes, and the decision stands to ease reimbursement challenges for healthcare providers and enables broader patient access.